From peak performance to practical robustness in radiopharmaceutical design

Radiopharmaceutical research and development has been largely driven by the pursuit of high radiochemical yield (RCY) under optimized laboratory conditions. However, this emphasis on peak performance often overlooks a critical translational bottleneck: insufficient robustness under the rigid operational constraints encountered in automated synthesis modules (ASMs) and multi-center clinical production. Recognizing the multi-faceted nature of clinical translation, this perspective focuses specifically on the chemical design phase as the primary origin of translational reliability. Many radiolabeling systems achieve high RCY only within narrow operational windows and exhibit pronounced sensitivity to minor perturbations in process parameters, reflecting intrinsic chemical fragility driven by kinetic constraints, trace metal interference, and radiolysis at clinically relevant activity levels. We argue that radiochemical robustness, defined as consistent yield and purity across a multidimensional design space defined by critical process parameters, should be considered a primary design criterion. This approach aligns with Quality by Design (QbD) principles, evaluated through tolerance to environmental variability, reproducibility across scales and activity levels, and compatibility with standardized automated platforms. Integrating robustness-driven principles with traditional performance optimization serves as a critical de-risking strategy to reduce translational failure. Without compromising strict quality thresholds, this approach better aligns radiopharmaceutical development with stringent regulatory and current Good Radiopharmacy Practice (cGRPP) requirements, ensuring high-quality medicinal products for maximum patient benefit. Radiochemical robustness should be established as a co-equal criterion alongside biological performance during initial probe selection to ensure long-term translational viability.